Biocon gains after Health Canada nod for cancer, osteoporosis drugs

Biocon shares rise after Health Canada approves Bosaya and Vevzuo denosumab biosimilars for osteoporosis and cancer bone conditions, stock up about 1.5 percent at 364.40

Leave a Reply

Your email address will not be published. Required fields are marked *